Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort in AMP-induced Asthma Model
NCT00272753Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of budesonide in asthma (4 arms), sponsored by AstraZeneca. Primary endpoint: Decrease in lung function (FEV1) after the third AMP provocation test at Day 1. Started Apr 2004; status: completed.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00272753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272753.